Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

IGI Laboratories, Inc. (IG) Appoints Dr. Kenneth Miller As Senior Vice President – R&D

|Includes: Teligent, Inc. (TLGT)

Yesterday, New Jersey-based generic topical pharmaceutical company IGI Laboratories announced that it has appointed Dr. Kenneth Miller as its Senior Vice President of R&D, effective December 17, 2012.

Jason Grenfell-Gardner, IGI's President and CEO, remarked, "Dr. Miller's appointment brings significant practical experience in generic topical pharmaceuticals and leadership that will allow us to accelerate the growth of our ANDA pipeline. This pipeline is the key to growing IGI's generic business, and we're excited to have Dr. Miller leading our R&D team."

Dr. Miller has an extensive career with over 20 years of topical and transdermal experience in branded and generic pharmaceutical product development. Prior to IGI, he held various leadership positions at Mylan Technologies, eventually rising to Senior Director in 2008. As head of product development, Dr. Miller oversaw the development of topical and transdermal patches, including Mylan's Fentanyl Transdermal System which received the DIANA Award for Best New Product Introduction in 2005.

In addition to his contributions to product development, Dr. Miller was responsible for technical evaluation of Mylan's intellectual property, with four US Patents and six World Patents on product design and manufacture. Additional patents are currently pending.

Prior to Mylan, Ken held positions in both industry and academia serving on the faculties of UAMS (Pharmaceutics), Penn State (Chemical Engineering), and Utah (Dermatology). He has a BSChE degree from Carnegie Mellon University, an MSChE degree from West Virginia University, and a PhD from the University of Florida.

For more information, visit

Please see disclaimer on the QualityStocks website: